Screener
Capricor Therapeutics CAPR Business Segments — Interest Expense Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Capricor Therapeutics’s 10-K, filed March 17, 2026.
- Filed
- Mar 17, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-029580
| Line item | Years ended December 31, 2025 | Years ended December 31, 2024 |
|---|---|---|
| OTHER INCOME (EXPENSE) | ||
| Other income | 45,421 | 7,471 |
| Investment income | 6,257,607 | 2,202,990 |
| Interest expense | (3,045,725) | — |
| Loss on disposal of fixed assets | (157,519) | (112,805) |
| TOTAL OTHER INCOME (EXPENSE) | 3,099,784 | 2,097,656 |
| LOSS BEFORE INCOME TAXES | (105,042,346) | (40,465,586) |
| (Provision for) benefit from income taxes | (1,600) | (1,600) |
ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Capricor Therapeutics's business segments — interest expense nonoperating?
- Capricor Therapeutics (CAPR) reported business segments — interest expense nonoperating of $761.43K in Q4 2025.
- What does business segments — interest expense nonoperating mean?
- This reflects the costs incurred by the company for servicing debt or other financial obligations that are not part of core operating expenses. It indicates the company's reliance on external financing and the associated cost of capital. High interest expenses can significantly impact the net cash position of a development-stage company.
Ask your AI about Capricor Therapeutics's business segments — interest expense nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude